Efficacy of the CV‑MED regimen in treating extramedullary involvement of multiple myeloma: A case report.

Extramedullary progression of multiple myeloma (MM) is commonly associated with a poor prognosis. However, optimal management strategies have not yet been established for the treatment of extramedullary involvement in MM. The present study reports the case of a 59-year-old female patient with MM who experienced extramedullary progression after two cycles of first-line VRD (bortezomib, lenalidomide and dexamethasone) therapy. The patient achieved remission of the extramedullary lesion following treatment with an innovative CV-MED regimen, which includes chidamide, bortezomib, mitoxantrone hydrochloride liposome, etoposide and dexamethasone. Subsequently, the patient underwent autologous hematopoietic stem cell harvesting and maintenance therapy, and remains in a progression-free survival state. The present case suggests that a chemotherapy regimen incorporating mitoxantrone hydrochloride liposomes, chidamide and bortezomib could be a promising treatment strategy for managing extramedullary involvement in MM.